Reaction
Abdominal Operation reporting signals
As of the last recalculation, Abdominal Operation appears in 1,260 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 18.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Risankizumab-Rzaa | 85 | 18.3 | 18.4 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 7 | 13.5 | 13.5 |
| Aprepitant | 12 | 10.8 | 10.8 |
| Pancrelipase | 23 | 10.0 | 10.0 |
| Upadacitinib | 42 | 8.8 | 8.8 |
| Testosterone Cypionate | 4 | 7.4 | 7.4 |
| Vilazodone Hydrochloride | 4 | 7.2 | 7.2 |
| Niraparib | 9 | 6.7 | 6.7 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 5 | 6.6 | 6.6 |
| Sodium Oxybate | 23 | 5.9 | 5.9 |
| Esketamine Hydrochloride | 5 | 4.6 | 4.6 |
| Sarilumab | 5 | 3.1 | 3.1 |
| Abaloparatide | 5 | 2.8 | 2.8 |